Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628706 | 1.00 | KMT2A (0.58) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1709762 | 1.00 | KMT2A (0.58) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4142005 | 0.89 | KMT2A (0.51) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3375103 | 0.89 | KMT2A (0.58) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL640977 | 0.89 | KMT2A (0.58) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10962850 | 0.89 | KMT2A (0.51) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2851129 | 0.89 | KMT2A (0.58) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18395170 | 0.87 | KMT2A (0.57) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18395608 | 0.87 | KMT2A (0.57) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18395173 | 0.87 | KMT2A (0.57) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694630-B1 | METHOD FOR PRODUCING CHIRAL OR ENANTIOMER-ENRICHED BETA-AMINO ACIDS, -ALDEHYDES, -KETONES AND GAMMA-AMINO ALCOHOLS | DSM FINE CHEM AUSTRIA GMBH (AT) | 2008-05-07 | — | — | EP | disclosed |
| US-20070123589-A1 | Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123589-A1 | Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols | GLRA1, GLRB, GLRA2 | KMT2A 1115/4885LMNA 2937/4885SMN1; SMN2 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.